Skip to main content

Table 3 Preventive effect of C1-INH (SC) within 2 weeks of treatment initiation

From: Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study

 

40 IU/kg (N = 45)

60 IU/kg (N = 45)

C1-INH (SC)

Placebo

C1-INH (SC)

Placebo

Number of patients

43

44

43

42

Number of patients with HAE attacks (%)

12 (28)

39 (89)

10 (23)

34 (81)

Number of HAE attacks

27

78

14

70

Number (%) of HAE attacks by severity

 Mild

9 (33)

16 (21)

9 (64)

22 (31)

 Moderate

10 (37)

39 (50)

5 (36)

31 (44)

 Severe

8 (30)

23 (29)

0

17 (24)

  1. C1-INH: C1-esterase inhibitor; HAE: hereditary angioedema; N: number of patients in the intention-to-treat population; SC: subcutaneous